PubMed Health⌕ Search

PubMed · 17025429

Computer simulation of diffusion-limited cluster-cluster aggregation with an Epstein drag force.

Abstract

The motion of particles, dispersed in a medium, between collisions with each other can, in limiting situations, be either ballistic (straight line) or diffusive (random walker). The diffusive regime can be divided into two distinct subregimes. The "continuum regime" exhibits Stokes-Einstein-type diffusion (no-slip surface boundary condition) with a frictional coefficient proportional to the particle size (linear dimension). The "Epstein regime," as we shall refer to it, is characterized by a frictional coefficient proportional to the particle cross-sectional area, hence an Epstein-type diffusion (slip surface). The purpose of the current study is to illuminate the dynamics of dilute-limit aggregation in the Epstein regime. We present results from low volume fraction Monte Carlo simulations of cluster-cluster aggregation in the Epstein regime with the particle motion based on each particle's cross-sectional area. Our findings indicate that aggregates grown under Epstein conditions have a fractal dimension of approximately 1.8, similar to that of diffusion-limited cluster-cluster aggregates (DLCA) in the continuum regime. The kinetic exponent z in the Epstein regime is found to be z approximately 0.8, lower than its value for both the continuum regime DLCA (z = 1) and for the ballistic cluster aggregation regime (z approximately 2). Cluster size distribution data for Epstein systems are found to scale at large cluster sizes with exponents consistent with the kinetic data. A scaling argument for predicting the kinetic exponent and kernel homogeneity based on the mass or size dependence of the particle velocity and collision cross section is presented and is seen to give accurate results for dilute and intermediate values of particle volume fractions not only for the current study, but also for work done by other researchers with various choices for the aggregation kernel.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

F Pierce, C M Sorensen, A Chakrabarti. 2006-08-25. Computer simulation of diffusion-limited cluster-cluster aggregation with an Epstein drag force.. https://doi.org/10.1103/physreve.74.021411

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗